Browsing Tag
Non-small cell lung cancer
42 posts
CStone targets European expansion with EMA filing for Sugemalimab in stage III NSCLC
CStone Pharmaceuticals seeks EMA approval for sugemalimab in stage III NSCLC, aiming to expand lung cancer immunotherapy options in Europe.
Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking…
Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) in combination with chemotherapy…
Xencor stock skyrockets 26% overnight after breakthrough in cancer research
Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by…
Instil Bio makes shock move: Shuts down UK operations and slashes jobs
Instil Bio, Inc., a clinical-stage biopharmaceutical company headquartered in Dallas, Texas, is undergoing a significant restructuring that includes…
EC approves AstraZeneca’s Tagrisso with chemotherapy for EGFR-mutated lung cancer
AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination…
RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life…
Avistone Biotechnology receives NMPA approval for Vebreltinib in China
Avistone Biotechnology Co. Ltd., a precision oncology therapeutics company, has announced the conditional approval from the National Medical…
AstraZeneca’s PACIFIC-2 Phase 3 trial for Imfinzi in NSCLC falls short of primary endpoint
In the latest development in oncology research, AstraZeneca’s PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with…
Mirati Therapeutics secures UK approval for KRAZATI in advanced NSCLC
Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK’s Medicines and…